十一月 2025
- Home
- Marinus Pharma
十一月 2025的Marinus Pharma市场份额分析
Our Areas of Focus With patients at the core of everything we do, we are continuously seeking ways to improve the treatment paradigm for patients with rare genetic epilepsies and seizure disorders. Status Epilepticus (SE) Status epilepticus is the occurrence of an epileptic seizure of a prolonged duration of more than five minutes or several
Marinus Pharma(包含公司地区分支机构)
查看更多网站流量和参与度信息- marinuspharma.com
Marinus Pharma收入截至 十一月 2025为 15M - 25M
Marinus Pharma主要域名产生的收入
3 年中Marinus Pharma主要域名的收入
Marinus Pharma主要域名的收入
Marinus Pharma热门域名的总访问量
了解Marinus Pharma市场份额和潜在市场覆盖范围。
过去 3 个月的总访问量
子公司明细
Marinus Pharma热门域名的平均访问时长
分析Marinus Pharma参与度指标。
过去 3 个月的平均访问时长
子公司明细
Marinus Pharma热门域名的平均页面浏览量
了解Marinus Pharma如何保持用户参与度、培养用户兴趣和鼓励采取后续操作。
过去 3 个月的平均页面浏览量
子公司明细
想要获取更深入的流量洞见?
过滤超过 2030 万家在线企业。发现流量激增的新潜在客户,开始或停止使用技术的新潜在客户,或者获得正面报道的新潜在客户。
Marinus Pharma 的新闻与信号
借助 Similarweb 销售信号提醒,每当在目标受众之中出现新的机会或威胁时,您都会收到所识别出购买信号的每日更新。
新闻Ovid Therapeutics Inc. partnered with Marinus Pharmaceuticals, Inc. on Feb 1st '22.In February 2022, Ovid entered into an exclusive patent license agreement with Marinus Pharmaceuticals, Inc.('Marinus') related to the use of ganaxolone in CDKL5 deficiency disorder (CDD).
六月 25, 2025阅读更多
新闻Marinus Pharmaceuticals, Inc. has issues with possible breaches of fiduciary duty and other violations of law in its transaction with the Immedica.Ademi LLP is investigating Marinus (Nasdaq: MRNS) for possible breaches of fiduciary duty and other violations of law in its transaction with the Immedica.
十二月 30, 2024阅读更多
新闻Classaction filed suit against Marinus Pharmaceuticals, Inc. on Aug 5th '24.Class Action filed against Marinus Pharmaceuticals, Inc. (MRNS) - August 5, 2024 deadline to join - contact Levi & Korsinsky.
七月 10, 2024阅读更多
查看 Marinus Pharma 的所有信号
让您的销售团队专注于最有希望的机会。通过分清机会的轻重缓急并在合适的时机介入,您可以优化工作并达成更多交易。